Monday, biotechnology company Idera Pharmaceuticals, Inc. (IDRA) announced positive interim results from a Phase 1 clinical trial of IMO-2125 in patients with chronic hepatitis C virus infection.
IMO-2125 is an agonist of Toll-like Receptor 9 that Idera designed to treat hepatitis C virus or HCV by inducing endogenous interferon-alpha and other Th1-type cytokines and chemokines. It is Idera's lead drug candidate for the treatment of chronic HCV infection.
Commenting on the results, Tim Sullivan, vice president of development programs said, "The interim data in the difficult-to-treat null responder HCV patient population through the first four dose levels of IMO-2125 in this four-week trial are very encouraging."
Sullivan added that based on these data, the company is extending the trial to a fifth dose level and is beginning to recruit patients in this cohort.
Idera indicated that in the interim four-week period, IMO-2125 was well tolerated. The drug also demonstrated a treatment-related decrease in viral load at escalating dose levels. All 41 patients enrolled in the trial are null responders, which is defined as patients who have failed to achieve a 2 log10 reduction in viral load during previous 12 to 24 weeks of treatment with pegylated recombinant interferon-alpha plus ribavirin, the current standard of care treatment. The trial is being conducted at six U.S. sites with a central laboratory for safety, immunology, and HCV RNA assessments.
The Cambridge, Massachusetts-based Idera plans to use the results from the ongoing Phase 1 clinical trial to guide its strategy for further development of IMO-2125 for the null responder HCV patient population.
Idera also indicated an ongoing second clinical trial of IMO-2125 in combination with ribavirin in treatment-naïve HCV patients, the results of which will guide the development strategy for IMO-2125 in this patient population.
IDRA is trading at $5.00, up $0.27 or 5.71%, on a volume of about 33 thousand shares.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.